Pal-GHK: hydrogel delivery application — WO2026046854A1
Mark Johnson, Samantha Williams, Mark O'MAHONY, Michael Bell · 2026 · WO2026046854A1 · patent family 92633954
Published 2026-03-05.
Reported patent results
Reported findings
The hydrogel produced a larger upper-skin mass-spectrometry signal and lower residual peptide in the removed hydrogel.
Ex-vivo porcine-skin delivery study comparing Pal-GHK hydrogel and a reference formulation; analytical imaging, not a clinical skin trial.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Upper-skin ion-signal AUC | 12,114.5 hydrogel versus 1,928.4 reference formulation; reported as greater than sixfold | Analytical imaging signal; not blood exposure or clinical response · 2-hour Franz-cell experiment |
| Residual hydrogel peptide | Approximately 10% detectable compared with unused hydrogel, across 9 pieces | The inventor interprets this as >90% delivery; loss from the hydrogel is not a complete mass-balance proof of skin absorption · 2 hours |
Porcine skin, analytical ion intensity and residual-product measurements do not establish human bioavailability, wrinkle reduction or systemic delivery.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Formulation. A 2026 hydrogel-composition application includes Pal-GHK in a dependent claim and delivery examples.
Skin-delivery experiments do not demonstrate human anti-aging benefit; the claimed composition is not a patent on all GHK-Cu products.
- Publication
- WO2026046854A1 ↗ · 2026-03-05
- Earliest priority / filing
- 2024-08-30 / 2025-08-22
- Original applicant / assignee
- Boots Co PLC
- Indexed status
- Pending · checked 2026-11-06
- Patent family
- 92633954 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Peptide containing hydrogel compositions
Inventors: Mark Johnson; Samantha Williams; Mark O'MAHONY; Michael Bell.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Skin-delivery experiments do not demonstrate human anti-aging benefit; the claimed composition is not a patent on all GHK-Cu products.
- Porcine skin, analytical ion intensity and residual-product measurements do not establish human bioavailability, wrinkle reduction or systemic delivery.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-92633954. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Mark Johnson, Samantha Williams, Mark O'MAHONY, Michael Bell. Pal-GHK: hydrogel delivery application — WO2026046854A1 WO2026046854A1 · patent family 92633954 2026.
Molekul research summary: https://molekul.io/research/patent-wo2026046854a1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry